PA8464601A1 - Combinaciones de estatina-eter carboxialquilico - Google Patents

Combinaciones de estatina-eter carboxialquilico

Info

Publication number
PA8464601A1
PA8464601A1 PA19988464601A PA8464601A PA8464601A1 PA 8464601 A1 PA8464601 A1 PA 8464601A1 PA 19988464601 A PA19988464601 A PA 19988464601A PA 8464601 A PA8464601 A PA 8464601A PA 8464601 A1 PA8464601 A1 PA 8464601A1
Authority
PA
Panama
Prior art keywords
statin
combinations
carboxyalkyl ether
ether
carboxyalkyl
Prior art date
Application number
PA19988464601A
Other languages
English (en)
Spanish (es)
Inventor
Charles Larry Bisgaier
Roger Schofield Newton
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PA8464601A1 publication Critical patent/PA8464601A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
PA19988464601A 1997-12-12 1998-12-11 Combinaciones de estatina-eter carboxialquilico PA8464601A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6937597P 1997-12-12 1997-12-12

Publications (1)

Publication Number Publication Date
PA8464601A1 true PA8464601A1 (es) 2001-12-14

Family

ID=22088573

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19988464601A PA8464601A1 (es) 1997-12-12 1998-12-11 Combinaciones de estatina-eter carboxialquilico

Country Status (30)

Country Link
EP (1) EP1045691B1 (enExample)
JP (1) JP2002508320A (enExample)
KR (1) KR20010033003A (enExample)
AR (1) AR017851A1 (enExample)
AT (1) ATE285762T1 (enExample)
AU (1) AU754089B2 (enExample)
BR (1) BR9813542A (enExample)
CA (1) CA2304612A1 (enExample)
CO (1) CO4970816A1 (enExample)
CR (1) CR5926A (enExample)
CU (1) CU20000140A7 (enExample)
DE (1) DE69828442T2 (enExample)
DK (1) DK1045691T3 (enExample)
ES (1) ES2230733T3 (enExample)
GT (1) GT199800196A (enExample)
HN (1) HN1998000185A (enExample)
HU (1) HUP0004547A3 (enExample)
IL (1) IL135349A0 (enExample)
IS (1) IS2150B (enExample)
MY (1) MY118381A (enExample)
NO (1) NO20002966D0 (enExample)
NZ (1) NZ503982A (enExample)
PA (1) PA8464601A1 (enExample)
PE (1) PE20000017A1 (enExample)
PL (1) PL341066A1 (enExample)
PT (1) PT1045691E (enExample)
SV (1) SV1998000146A (enExample)
UY (1) UY25299A1 (enExample)
WO (1) WO1999030704A1 (enExample)
ZA (1) ZA9811348B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105154A1 (en) 2001-10-24 2003-06-05 Bisgaier Charles Larry Statin-carboxyalkylether combinations
US6861555B2 (en) 2000-01-25 2005-03-01 Warner-Lambert Company Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
KR20010033017A (ko) * 1997-12-12 2001-04-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 과지질혈증 치료제인 스타틴-ＬＰ(ａ) 억제제의 병용 제제
SK4122001A3 (en) * 1998-09-30 2002-06-04 Warner Lambert Co Method for preventing or delaying catheter-based revascularization
US6562864B1 (en) * 1999-09-02 2003-05-13 Drake Larson Catechin multimers as therapeutic drug delivery agents
IN191580B (enExample) * 1999-12-17 2003-12-06 Ranbaxy Lab Ltd
GEP20053428B (en) 2000-01-25 2005-01-25 Warner Lambert Co Calcium Dicarboxylate Ethers, Methods of Making Same, and Treatment of Vascular Disease and Diabetes Therewith
AU2001256278A1 (en) * 2000-04-18 2001-10-30 Bayer Aktiengesellschaft Use of cse inhibitors for treating heart failure
SK15132002A3 (sk) * 2000-04-26 2003-08-05 Warner-Lambert Company Antihypertenzné činidlá a ich použitie
US6689807B1 (en) * 2000-06-08 2004-02-10 Caritas St. Elizabeth's Medical Center Of Boston, Inc. HMG CoA reductase inhibitors for promoting angiogenesis
HUP0500616A3 (en) * 2001-08-16 2011-07-28 Teva Pharma Processes for preparing calcium salt forms of statins
KR20040026705A (ko) 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
US20050026979A1 (en) * 2003-07-31 2005-02-03 Maha Ghazzi Methods for treating inflammation and inflammation-associated diseases with a statin and ether
WO2013103842A1 (en) * 2012-01-06 2013-07-11 Michigan Life Therapeutics, Llc Methods of reducing risk of cardiovascular disease
JP2018536710A (ja) 2015-11-06 2018-12-13 ジェンファイア・セラピューティクス・インコーポレイテッドＧｅｍｐｈｉｒｅ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 混合型脂質異常症の治療

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases

Also Published As

Publication number Publication date
NZ503982A (en) 2002-03-28
CA2304612A1 (en) 1999-06-24
CO4970816A1 (es) 2000-11-07
EP1045691B1 (en) 2004-12-29
JP2002508320A (ja) 2002-03-19
MY118381A (en) 2004-10-30
ES2230733T3 (es) 2005-05-01
CU20000140A7 (es) 2005-10-19
WO1999030704A1 (en) 1999-06-24
CR5926A (es) 2000-03-06
HUP0004547A2 (hu) 2001-05-28
IL135349A0 (en) 2001-05-20
PL341066A1 (en) 2001-03-26
BR9813542A (pt) 2000-10-10
HN1998000185A (es) 1999-06-02
DE69828442D1 (de) 2005-02-03
UY25299A1 (es) 2001-08-27
PT1045691E (pt) 2005-03-31
IS2150B (is) 2006-10-13
ATE285762T1 (de) 2005-01-15
EP1045691A1 (en) 2000-10-25
AR017851A1 (es) 2001-10-24
DK1045691T3 (da) 2005-03-14
ZA9811348B (en) 1999-06-14
AU1591599A (en) 1999-07-05
DE69828442T2 (de) 2005-06-02
SV1998000146A (es) 1999-09-30
AU754089B2 (en) 2002-11-07
PE20000017A1 (es) 2000-01-20
IS5445A (is) 2000-04-14
GT199800196A (es) 2000-06-03
HUP0004547A3 (en) 2001-12-28
NO20002966L (no) 2000-06-09
NO20002966D0 (no) 2000-06-09
KR20010033003A (ko) 2001-04-25

Similar Documents

Publication Publication Date Title
PA8464601A1 (es) Combinaciones de estatina-eter carboxialquilico
AR018777A1 (es) Composicion farmaceutica que contiene una combinacion de una estatina y aspirina y metodo.
MX9702175A (es) Combinacion de un inhibidor de absorcion de colesterol y un inhibidor de sintesis de colesterol.
DE69827821D1 (de) Synergistisch,analgetische zusammensetzung mit opiod-analgetika und zyklooxygenase-2 inhibitoren
ES2178298T3 (es) Compuestos anti-inflamatorios.
AP2003002743A0 (en) Therapeutic combination of a cept inhibitor and atorvastatin
UY25714A1 (es) Método para tratar ateroesclerosis empleando un inhibidor de ap2 y combinación.
GT200300053A (es) Compuestos que modulan la actividad de ppar
GT200300054A (es) Compuestos que modulan la actividad de ppar
ES2176755T3 (es) Derivados anticonvulsivos utiles para el tratamiento de la esclerosis lateral amiotrofica.
AR020999A1 (es) Composiciones y proceso para la elaboracion de isotretinoina
CL2004000026A1 (es) Uso de una composicion que comprende 0 a alrededor de 29% de cis-clomifeno y de alrededor de 100 a alrededor de 71% de trans-clomifeno para preparar un medicamento util para aumentar los niveles de testosterona en suero en un mamifero masculino.
BR0213181A (pt) Combinações de inibidor de cox-2
BRPI0518300A2 (pt) derivados de Ácido 7-(2h-pirazol-3-il)-3,5-diidràxi-heptanàico como inibidores da hmg co-a reductase para o tratamento de lipidemia
ES2189072T3 (es) Nuevo benzo-cicloalquenos heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ECSP982777A (es) Combinaciones de estatina- - eter carboxialquilico.
UY26218A1 (es) Combinacion de inhibidores de mtp e inhibidores de hmg- coa reductasa y su uso en medicamentos. ley 17.164.-
BR9813539A (pt) Combinações de inibidor de lp(a) e estatina anti-hiperlipidêmicas
DOP2001000150A (es) Agente hipertensivo y su uso
PA8469001A1 (es) Combinaciones de estatina-inhibidor de mmp.
ES2048139T1 (es) Procedimiento para la eliminacion de madera impregnada con aceite de alquitran.
AU1653100A (en) Use of diminazene-di-aceturate for treating malaria
ES2166590T3 (es) Procedimiento y compuestos intermedios para la preparacion de compuestos fluoroolefinicos plaguicidas.
ECSP992885A (es) Combinaciones de estatina-inhibidor de mmp
ECSP003541A (es) COMBINACION DE INHIBIDORES DE MTP E INHIBIDORES DE HMG CoA REDUCTASA Y SU USO EN MEDICAMENTOS